The European Commission has granted a European Marketing Authorisation for DuoCort Pharma’s Plenadren, an orphan drug used to treat adrenal insufficiency in adults.

Plenadren, an oral once-daily tablet, is a dual-release hydrocortisone replacement therapy.

The move follows the satisfactory opinion adopted by the Committee for Medicinal Products for Human Use.

DuoCort Pharma chief medical officer Gudmundur Johannsson said Plenadren could be a new cortisol replacement therapy for patients suffering from adrenal insufficiency.

Currently, Plenadren is approved in all European Union countries, Iceland, Norway and Lichtenstein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.